Gelofusine (Succinylated Gelatin 4%)
Gelofusine is a plasma volume expander indicated for volume replacement during surgery, trauma, and therapeutic plasma exchange, but it should NOT be used as a first-line resuscitation fluid in trauma or major hemorrhage based on current guidelines.
Critical Context Issue
The provided FDA drug label 1 appears to be for an antifungal medication (likely caspofungin), not Gelofusine. This is clearly a data error, as the content describes treatment of fungal infections rather than a colloid solution. Therefore, I will rely on guideline evidence and research data for this response.
Indications
Gelofusine (4% succinylated gelatin in 0.7% saline, molecular weight 30 kDa) is used for:
- Perioperative volume replacement during elective surgery 2, 3
- Therapeutic plasma exchange procedures as a replacement fluid 4
- Washing cryopreserved hematopoietic stem cells prior to infusion 5
Important Contraindication from Guidelines
Gelofusine should be AVOIDED during uncontrolled hemorrhage in trauma settings 6. The 2016 AAGBI guidelines explicitly state: "Avoid crystalloid and colloid administration during uncontrolled haemorrhage" 6. This represents a paradigm shift in trauma resuscitation.
Dosing
Adult Dosing
- Standard volume loading: 1 liter infused over 1 hour 2, 3
- Rapid resuscitation (when indicated): Up to 51 ml/kg may be required in severe reactions, though this represents an extreme case 7
Pediatric Dosing
While not specifically addressed for Gelofusine in the evidence, the AAGBI guidelines provide general colloid dosing for children:
- Volume-based prescription: 10-15 ml/kg as needed 6
- Prescribe by volume rather than units in pediatric patients
Contraindications & Warnings
Absolute Contraindications
Serious Adverse Events
- Anaphylaxis: Documented cases requiring massive fluid resuscitation and vasopressor support 7
- Serious adverse event rate: <5% in clinical apheresis procedures 4
Important Caveats
- Hyperchloremic acidosis risk: Gelofusine causes greater increases in serum chloride and larger decreases in strong ion difference compared to some alternatives 2
- Low-molecular-weight proteinuria: Causes marked increase in urinary β2-microglobulin (from 0.06 to 43.52 μg/min) and α1-microglobulin excretion through competitive inhibition of tubular protein reabsorption 8
- This does NOT indicate renal tubular injury (β-NAG remains unchanged)
- Important consideration when interpreting urinary protein levels in ICU patients
Monitoring Requirements
During Infusion
- Vital signs: Blood pressure, heart rate (minimal hemodynamic effects expected) 3
- Anaphylaxis surveillance: Immediate recognition capability, especially during cardiac surgery 7
Laboratory Monitoring
- Serum electrolytes: Particularly chloride and bicarbonate 2
- Hematocrit: To assess volume expansion effect 2, 3
- Urinary protein interpretation: Expect elevated low-molecular-weight proteins without clinical significance 8
Post-Infusion
- Renal function: Monitor for changes, though proteinuria is expected and benign 8
- Acid-base status: Assess for hyperchloremic metabolic acidosis 2
Clinical Pharmacology
Volume Expansion Characteristics
- Intravascular retention: At end of 1-liter infusion, 79% remains intravascular (21% extravasates) 3
- Duration of effect: Similar to 6% hydroxyethyl starch despite 100 kDa molecular weight difference 2, 3
- Blood volume expansion: Significantly superior to 0.9% saline (68% of saline extravasates vs. 21% of Gelofusine) 3
Hormonal Effects
Cost-Effectiveness
Gelofusine is 93% cheaper than 5% human albumin ($1.28 vs. $19.43 per 100 ml), making it particularly valuable in low/middle-income countries 4. The main barrier to adoption is its omission from ASFA guidelines 4.
Special Applications
Therapeutic Plasma Exchange
Gelofusine is safe and economical for procedures where plasma replacement is not specifically required 4. It should be considered as a first-line replacement fluid in resource-limited settings.
Hematopoietic Stem Cell Processing
Gelofusine demonstrates superior cell viability compared to traditional Dextran40-based solutions:
Nephroprotection
Emerging evidence suggests Gelofusine may reduce polymyxin B-associated nephrotoxicity by decreasing cellular drug uptake and oxidative stress 9, though this requires further clinical validation.
Common Pitfalls
- Using Gelofusine in trauma resuscitation: This violates current damage control resuscitation principles 6
- Misinterpreting proteinuria: The low-molecular-weight proteinuria is expected and does not indicate renal injury 8
- Inadequate anaphylaxis preparedness: Have vasopressors and large-volume resuscitation capability immediately available 7
- Ignoring acid-base effects: Monitor for hyperchloremic acidosis, particularly with large volumes 2